Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kluth

Showing results (541-550 of 1,145) with videos related to

Pageof 115
Sort By:
BMC Cancer|March 3, 2019
Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancerCornelia Schroeder, Jan Grell, Claudia Hube-Magg, et al.
Clinical Genitourinary Cancer|December 15, 2021
Contemporary Trends and Efficacy of Pelvic Lymph Node Dissection at Radical Cystectomy for Urothelial and Variant Histology Carcinoma of the Urinary BladderMarina Kosiba, L Franziska Stolzenbach, Claudia Collà Ruvolo, et al.
European Heart Journal|January 19, 2019
A novel role for myeloid endothelin-B receptors in hypertensionAlicja Czopek, Rebecca Moorhouse, Léa Guyonnet, et al.
Urologic Oncology|July 21, 2020
Obesity is associated with adverse short-term perioperative outcomes in patients treated with open and robot-assisted radical cystectomy for bladder cancerMarina Deuker, L Franziska Stolzenbach, Claudia Collà Ruvolo, et al.
European Urology Focus|September 23, 2020
Micropapillary Versus Urothelial Carcinoma of the Urinary Bladder: Stage at Presentation and Efficacy of Chemotherapy Across All Stages-A SEER-based StudyMarina Deuker, L Franziska Stolzenbach, Claudia Collà Ruvolo, et al.
Carcinogenesis|September 23, 2015
Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parametersNathaniel Melling, Erik Thomsen, Maria Christina Tsourlakis, et al.
International Journal of Cancer|September 19, 2015
Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancersChristoph Burdelski, Sandra Kleinhans, Martina Kluth, et al.
World Journal of Urology|April 19, 2020
High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinomaTill Eichenauer, Luca Simmendinger, Christoph Fraune, et al.
Prostate Cancer and Prostatic Diseases|May 31, 2021
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysisMike Wenzel, Luigi Nocera, Claudia Collà Ruvolo, et al.
International Journal of Molecular Sciences|April 21, 2015
VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomyMaria Christina Tsourlakis, Puya Khosrawi, Philipp Weigand, et al.
Pageof 115

Showing results (541-550 of 1,145) with videos related to

Sort By:
Pageof 115
BMC Cancer|March 3, 2019
Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancerCornelia Schroeder, Jan Grell, Claudia Hube-Magg, et al.
Clinical Genitourinary Cancer|December 15, 2021
Contemporary Trends and Efficacy of Pelvic Lymph Node Dissection at Radical Cystectomy for Urothelial and Variant Histology Carcinoma of the Urinary BladderMarina Kosiba, L Franziska Stolzenbach, Claudia Collà Ruvolo, et al.
European Heart Journal|January 19, 2019
A novel role for myeloid endothelin-B receptors in hypertensionAlicja Czopek, Rebecca Moorhouse, Léa Guyonnet, et al.
Urologic Oncology|July 21, 2020
Obesity is associated with adverse short-term perioperative outcomes in patients treated with open and robot-assisted radical cystectomy for bladder cancerMarina Deuker, L Franziska Stolzenbach, Claudia Collà Ruvolo, et al.
European Urology Focus|September 23, 2020
Micropapillary Versus Urothelial Carcinoma of the Urinary Bladder: Stage at Presentation and Efficacy of Chemotherapy Across All Stages-A SEER-based StudyMarina Deuker, L Franziska Stolzenbach, Claudia Collà Ruvolo, et al.
Carcinogenesis|September 23, 2015
Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parametersNathaniel Melling, Erik Thomsen, Maria Christina Tsourlakis, et al.
International Journal of Cancer|September 19, 2015
Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancersChristoph Burdelski, Sandra Kleinhans, Martina Kluth, et al.
World Journal of Urology|April 19, 2020
High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinomaTill Eichenauer, Luca Simmendinger, Christoph Fraune, et al.
Prostate Cancer and Prostatic Diseases|May 31, 2021
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysisMike Wenzel, Luigi Nocera, Claudia Collà Ruvolo, et al.
International Journal of Molecular Sciences|April 21, 2015
VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomyMaria Christina Tsourlakis, Puya Khosrawi, Philipp Weigand, et al.
Pageof 115